By facilitating the release of ATP and the surface exposure of calreticulin, ferroptosis inducers like Erastin, which targets Xc-, and Ogremorphin, which targets GPR68, provide a promising avenue for enhancing the efficacy of immunotherapies in glioblastoma. The gene discussed is CALR; the disease is glioblastoma.